142 related articles for article (PubMed ID: 17266024)
1. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines.
Monaco SE; Angelastro JM; Szabolcs M; Greene LA
Int J Cancer; 2007 May; 120(9):1883-90. PubMed ID: 17266024
[TBL] [Abstract][Full Text] [Related]
2. ATF5 is overexpressed in epithelial ovarian carcinomas and interference with its function increases apoptosis through the downregulation of Bcl-2 in SKOV-3 cells.
Chen A; Qian D; Wang B; Hu M; Lu J; Qi Y; Liu DX
Int J Gynecol Pathol; 2012 Nov; 31(6):532-7. PubMed ID: 23018213
[TBL] [Abstract][Full Text] [Related]
3. Interference with ATF5 function enhances the sensitivity of human pancreatic cancer cells to paclitaxel-induced apoptosis.
Hu M; Wang B; Qian D; Li L; Zhang L; Song X; Liu DX
Anticancer Res; 2012 Oct; 32(10):4385-94. PubMed ID: 23060563
[TBL] [Abstract][Full Text] [Related]
4. Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5.
Angelastro JM; Canoll PD; Kuo J; Weicker M; Costa A; Bruce JN; Greene LA
Oncogene; 2006 Feb; 25(6):907-16. PubMed ID: 16170340
[TBL] [Abstract][Full Text] [Related]
5. Regulation of the human CHOP gene promoter by the stress response transcription factor ATF5 via the AARE1 site in human hepatoma HepG2 cells.
Yamazaki T; Ohmi A; Kurumaya H; Kato K; Abe T; Yamamoto H; Nakanishi N; Okuyama R; Umemura M; Kaise T; Watanabe R; Okawa Y; Takahashi S; Takahashi Y
Life Sci; 2010 Aug; 87(9-10):294-301. PubMed ID: 20654631
[TBL] [Abstract][Full Text] [Related]
6. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
Müllauer L; Mosberger I; Grusch M; Rudas M; Chott A
J Pathol; 2000 Jan; 190(1):20-30. PubMed ID: 10640988
[TBL] [Abstract][Full Text] [Related]
7. Targeting ATF5 in Cancer.
Angelastro JM
Trends Cancer; 2017 Jul; 3(7):471-474. PubMed ID: 28718401
[TBL] [Abstract][Full Text] [Related]
8. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.
Bishop JA; Sharma R; Illei PB
Hum Pathol; 2010 Jan; 41(1):20-5. PubMed ID: 19740516
[TBL] [Abstract][Full Text] [Related]
9. Re-expression of transcription factor ATF5 in hepatocellular carcinoma induces G2-M arrest.
Gho JW; Ip WK; Chan KY; Law PT; Lai PB; Wong N
Cancer Res; 2008 Aug; 68(16):6743-51. PubMed ID: 18701499
[TBL] [Abstract][Full Text] [Related]
10. The transcription factor ATF5: role in neurodevelopment and neural tumors.
Greene LA; Lee HY; Angelastro JM
J Neurochem; 2009 Jan; 108(1):11-22. PubMed ID: 19046351
[TBL] [Abstract][Full Text] [Related]
11. Regression/eradication of gliomas in mice by a systemically-deliverable ATF5 dominant-negative peptide.
Cates CC; Arias AD; Nakayama Wong LS; Lamé MW; Sidorov M; Cayanan G; Rowland DJ; Fung J; Karpel-Massler G; Siegelin MD; Greene LA; Angelastro JM
Oncotarget; 2016 Mar; 7(11):12718-30. PubMed ID: 26863637
[TBL] [Abstract][Full Text] [Related]
12. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas.
Bejarano PA; Baughman RP; Biddinger PW; Miller MA; Fenoglio-Preiser C; al-Kafaji B; Di Lauro R; Whitsett JA
Mod Pathol; 1996 Apr; 9(4):445-52. PubMed ID: 8729987
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of the promoter of human ATF5 gene.
Wei Y; Ge Y; Zhou F; Chen H; Cui C; Liu D; Yang Z; Wu G; Gu J; Jiang J
J Biochem; 2010 Aug; 148(2):171-8. PubMed ID: 20423929
[TBL] [Abstract][Full Text] [Related]
14. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
Wendroth SM; Mentrikoski MJ; Wick MR
Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392
[TBL] [Abstract][Full Text] [Related]
15. ATF5 is a highly abundant liver-enriched transcription factor that cooperates with constitutive androstane receptor in the transactivation of CYP2B6: implications in hepatic stress responses.
Pascual M; Gómez-Lechón MJ; Castell JV; Jover R
Drug Metab Dispos; 2008 Jun; 36(6):1063-72. PubMed ID: 18332083
[TBL] [Abstract][Full Text] [Related]
16. Protective neuronal induction of ATF5 in endoplasmic reticulum stress induced by status epilepticus.
Torres-Peraza JF; Engel T; Martín-Ibáñez R; Sanz-Rodríguez A; Fernández-Fernández MR; Esgleas M; Canals JM; Henshall DC; Lucas JJ
Brain; 2013 Apr; 136(Pt 4):1161-76. PubMed ID: 23518711
[TBL] [Abstract][Full Text] [Related]
17. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas.
Moll R; Mitze M; Frixen UH; Birchmeier W
Am J Pathol; 1993 Dec; 143(6):1731-42. PubMed ID: 8256859
[TBL] [Abstract][Full Text] [Related]
18. BCL-2 is a downstream target of ATF5 that mediates the prosurvival function of ATF5 in a cell type-dependent manner.
Dluzen D; Li G; Tacelosky D; Moreau M; Liu DX
J Biol Chem; 2011 Mar; 286(9):7705-13. PubMed ID: 21212266
[TBL] [Abstract][Full Text] [Related]
19. ATF5 increases cisplatin-induced apoptosis through up-regulation of cyclin D3 transcription in HeLa cells.
Wei Y; Jiang J; Sun M; Chen X; Wang H; Gu J
Biochem Biophys Res Commun; 2006 Jan; 339(2):591-6. PubMed ID: 16300731
[TBL] [Abstract][Full Text] [Related]
20. Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.
Hein S; Müller V; Köhler N; Wikman H; Krenkel S; Streichert T; Schweizer M; Riethdorf S; Assmann V; Ihnen M; Beck K; Issa R; Jänicke F; Pantel K; Milde-Langosch K
Breast Cancer Res Treat; 2011 Sep; 129(2):347-60. PubMed ID: 20972617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
